SURTIME

1. 01

   Systemic-first treatment is a selection strategy, not a universal prohibition on nephrectomy

2. 02

   Deferred nephrectomy has materially different timing interpretations

3. 03

   SURTIME is recalled as favorable, null or inconclusive, with substantial methodological caution

   Sample finding · free

   A podcast speaker asked what limitations, apart from sample size, matter when interpreting SURTIME’s immediate-versus-deferred nephrectomy comparison in intermediate-risk, clear-cell metastatic renal cancer.

   Source: podcast, 2024-02-18 · paraphrased; the full report links the source

4. 04

   Selection extends beyond risk labels, with unresolved subgroup and histology boundaries

5. 05

   Residual renal lesions and treatment-free goals leave the later-surgery decision unresolved

   Sample finding · free

   A podcast speaker asked whether removing a residual kidney lesion makes sense when long-term TKI therapy might be stopped or paused because of side effects or patient choice. The speaker also asked about kidney-sparing surgery for a remaining cystic lesion after treatment.

   Source: podcast, 2025-06-11 · paraphrased; the full report links the source

6. 06

   Favorable observational signals provoke a dispute about causal interpretation

7. 07

   Symptoms and tumor thrombus are consequential exceptions, but not agreed automatic surgical indications

8. 08

   Perioperative management is more definite for TKIs than for immunotherapy, while surgical complexity remains debated

9. 09

   Modern systemic choices change the application of sunitinib-era sequencing evidence

10. 10

    Neither surgery nor immediate systemic treatment is inevitable for every metastatic presentation

11. 11

    Primary-tumor radiation remains a separate approach; later Cytoshrink commentary limits the earlier rationale

12. 12

    Biological explanations and biomarkers are attractive but remain hypotheses or research tools

13. 13

    Patient preferences, preparation and experienced multidisciplinary care are part of the decision itself

The full report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified claims with exact source passages.

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

2022-07-26 → 2026-10-02

Cited window

2022-07-26 → 2026-10-02

Retrieved

2026-10-08

Title

Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma

Registry

NCT01099423

Study IDs

EORTC-30073 · EU-21022 · PFIZER-EORTC-30073

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Collaborators

Wales Cancer Trials Unit, Canadian Urologic Oncology Group, Institute of Cancer Research, United Kingdom

Design

Phase 3 · interventional, randomized, single group, phase3

Status

Unknown

Enrollment

99 actual

Start

2010-04 actual

Primary completion

2016-04 actual

Primary endpoint

Overall progression-free survival

Interventions

5 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
• –For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
• –11 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
• –1 further source limit is recorded in the machine-readable scope of this record.
• –The 34 retained commentary sources are not a count of independent HCPs and do not establish the prevalence of any view.
• –Discussion located through trial identifiers and aliases may miss unnamed references or different transcription variants.
• –One additional podcast could not be accessed; another transcript lacked additional audio verification, increasing uncertainty about exact wording.
• –Several consequential panel views cannot be attributed to a named speaker. Rosters and nearby named comments do not resolve ownership.
• –The full SURTIME publication text was unavailable. The supplied abstract nevertheless reports the null 28-week progression-free-rate result and a favorable nominal secondary intention-to-treat OS comparison; differing commentary remains attributed to each speaker rather than reconciled into one statistical assessment.
• –Some relevant discussion of treatment stopping, systemic-regimen toxicity and cost, surgical exceptions, radiation-study access and support, and biomarker plans is not included in the available synthesis. The retained views should not be read as complete accounts of those decisions.
• –Some social posts are truncated or omit outcome definitions, comparators and selection criteria. Their numerical summaries should not be treated as complete study reports.
• –Cross-cancer, non-clear-cell, oligoprogressive and non-metastatic evidence appears only as explicitly limited context or alternatives; it does not establish effects in SURTIME's clinical population.
• –The separate Cytoshrink commentary concerns early SBRT added to nivolumab/ipilimumab. Its null one-year PFS account, responder-only ongoing-response observation, intervention-arm imbalance and forthcoming OS/quality-of-life follow-up do not resolve nephrectomy sequencing.
• –Source dates are publication or post dates unless the source explicitly supplies other timing; they do not prove a change of mind across discussions.

How reports are built and checked: Methods.

Last checked Oct 8, 2026. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

release 1953726f4d49fe979f722e8ee5e35737fb8e098a6c579d12e5992947a45c1ba3

The same record as JSON or Markdown, or through the Erudio MCP server.

curl https://www.erudio.com/reports/surtime-nct01099423.json
curl https://www.erudio.com/reports/surtime-nct01099423.md

# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "surtime-01099423" })